Nuvectis Pharma, Inc.

Notes to the Unaudited Condensed Financial Statements

NOTE 1 – GENERAL:

The Company is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.

The Company has incurred net operating losses since its inception and had an accumulated deficit of $92.4 million as of September 30, 2025. The Company had cash and cash equivalents of $35.4 million as of September 30, 2025, and has not generated positive cash flows from operations. To date, the Company has primarily funded its operations through the issuance and sale of common stock.

During February 2025, the Company completed a public offering in which it received approximately $14.0 million in net proceeds, after deducting underwriting discounts and expenses, along with deducting other offering expenses (see Note 4).

During the three months ended September 30, 2025, the Company sold a total of 1,707,309 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $13.5 million at an average selling price of $7.94 per share, resulting in net proceeds of approximately $13.1 million after deducting issuance costs.

During the nine months ended September 30, 2025, the Company sold a total of 1,959,126 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $15.4 million at an average selling price of $7.88 per share, resulting in net proceeds of approximately $14.9 million after deducting issuance costs.

Management believes that its existing cash and cash equivalents as of September 30, 2025, enable the Company to fund planned operations for at least 12 months following the issuance date of these condensed financial statements.

The Company will need to raise additional capital to complete the clinical trials aimed at developing the product candidates, obtain regulatory and marketing approvals, and, if approved, for the commercialization of our product candidates. There can be no assurances that the Company will be able to secure such additional financing, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is unable to obtain sufficient funding, this could force the Company to delay, limit, or reduce its product development, clinical trials, commercialization efforts, or other operations, or even close down or liquidate.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

The accompanying condensed financial statements are unaudited. The unaudited condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), are stated in U.S. dollars, and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements, as certain footnotes or other financial information that U.S. GAAP normally requires can be condensed or omitted. The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements for the year ended 2024. The unaudited condensed financial statements include the accounts of the Company. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

In the opinion of management, the unaudited condensed financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods. The results for the period ended September 30, 2025, are not necessarily indicative of those expected for the year ending December 31, 2025, or for any future period. The condensed balance sheet as of December 31, 2024, included herein was derived from the audited financial statements as of that date but does not include all disclosures required by U.S. GAAP. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2025.

The significant accounting policies adopted and used in preparing the financial statements are consistent with those of the previous financial year.

The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.

The Company follows authoritative accounting guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. The Company’s Level 1 assets consist of money market funds.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, while also considering counterparty credit risk in its assessment of fair value.

During the three and nine months ended September 30, 2025 and 2024, there wereno transfers between fair value measure levels. Other financial instruments consist mainly of cash and cash equivalents, as well as other current assets, accounts payable, and accrued liabilities. The fair value of these financial instruments approximates their carrying values.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial position or results of operations. No new accounting standards were adopted during the period.

NOTE 3 – COMMITMENTS AND CONTINGENCIES:

CRT Pioneer Fund License Agreement

There have been no material changes to the CRT Pioneer Fund License Agreement, as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 25, 2025 (see Note 5a in the Notes to the Financial Statements in our Annual Report).

Any potential milestone or royalty payment amounts have not been accrued as of September 30, 2025, and December 31, 2024, due to the uncertainty related to the achievement of these events or milestones. On July 31, 2025, the Company issued its final data readout for NXP800 and ceased development of the compound at the current time.

University of Edinburgh License Agreement

There have been no material changes to the University of Edinburgh (“UoE”) License Agreement as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 25, 2025 (see Note 5a in the Notes to the Financial Statements in our Annual Report).

During the three and nine months ended September 30, 2025, the Company expensed $2.0 million in license fees associated with achieving certain milestones under the agreement. Any potential future research support, milestone, or royalty payment amounts have not been accrued as of September 30, 2025, and December 31, 2024, due to the uncertainty related to the achievement of these events, milestones, or commitments to additional research.

As of September 30, 2025, the Company has paid UoE $1.2 million of the total of up to $3.0 million related to the fundraising commitment. During the nine months ended September 30, 2025, the Company expensed $0.4 million, within research and development expenses, for licensee fees associated with the February 2025 public offering, which is included in the $1.2 million of payments towards the total fundraising commitment.

There have been no related party transactions except for those in the normal course of business as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 25, 2025 (see Note 10 in the Notes to the Financial Statements in our Annual Report on Form 10-K). See Note 5 for related party transactions related to the normal course of business.

As of September 30, 2025, and December 31, 2024, there areno contingent liabilities; therefore, no provision was made.

NOTE 4 – SHAREHOLDERS’ EQUITY:

On July 29, 2022, the Company closed a private placement offering (the “July 2022 Private Placement”), pursuant to the terms and conditions of a Securities Purchase Agreement (the “Agreement”), dated July 27, 2022. In connection with the July 2022 Private Placement, the Company issued 1,015,598 shares of common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 909,091 shares of common stock which were fully exercised as of December 31, 2022 and preferred investment options (the “Preferred Investment Options”) to purchase up to an aggregate of 1,924,689 shares of common stock. The Company agreed to pay the placement agent fee and management fee equal to 7.0% and 1.0%, respectively, of the aggregate gross proceeds from the July 2022 Private Placement, including the exercise of the Preferred Investment Options. The Preferred Investment Options became exercisable on January 23, 2023, and are exercisable through January 29, 2026, at an exercise price of $9.65 per share, subject to certain adjustments as defined in the Agreement. On July 15, 2025, the exercise period of the Preferred Investment Options was extended to January 29, 2028, with the other terms remaining unchanged. The effect of the change in terms resulted in an incremental fair value of the Preferred Investment Options of $2.4 million. It was treated as a reduction of income (increase of net loss) available to common stockholders in basic loss per share in accordance with the guidance in paragraph 260-10-45-15 (see Note 6). In the absence of retained earnings, the effect was charged to additional paid in capital and therefore did not result in any impact on equity. As of September 30, 2025,1,001,091 Preferred Investment Options were exercised for $8.9 million, net of fees, representing no new exercises during the nine months. In addition, as part of the July 2022 Private Placement, the Company issued warrants to the placement agent to purchase up to 115,481 shares of common stock. The placement agent warrants are in substantially the same form as the Preferred Investment Options, except that the exercise price is $10.31. As of September 30, 2025,79,104 placement agent warrants were exercised for which the Company has received $0.8 million, representing no new exercises during the nine months.

During the three months ended September 30, 2025, the Company sold a total of 1,707,309 common shares under its At-the-Market Offering Agreement (the “ATM Program”) for aggregate total gross proceeds of approximately $13.5 million at an average selling price of $7.94 per share, resulting in net proceeds of approximately $13.1 million after deducting issuance costs.

During the nine months ended September 30, 2025, the Company sold a total of 1,959,126 common shares under our ATM Program for aggregate total gross proceeds of approximately $15.4 million at an average selling price of $7.88 per share, resulting in net proceeds of approximately $14.9 million after deducting issuance costs.

As of September 30, 2025, approximately $45.8 million of securities remain available for sale under the ATM Program.

During February 2025, the Company completed a public offering in which it sold 3,105,000 shares of common stock at $5.00 per share, receiving net proceeds of $14.0 million after deducting underwriting discounts and commissions of $1.1 million and other offering expenses of $0.4 million.

NOTE 5 – SHARE-BASED PAYMENTS:

The following table summarizes the Company’s stock option activity in the Incentive Plan for the nine months ended September 30, 2025:

As of September 30, 2025, all share-based compensation expense has been recognized.

Restricted Stock Awards

Restricted stock awards (“RSAs”) have been granted to employees. The value of an RSA award is based on the Company’s share price on the date of grant. The Company granted RSAs in accordance with the Incentive Plan.

The following table summarizes the Company’s RSA activity for the nine months ended September 30, 2025, as described above, relating to the RSAs granted pursuant to the Incentive Plan:

As of September 30, 2025, there was $4.9 million of total unrecognized compensation cost related to RSAs expected to be recognized over a weighted average period of 1.43 years.

On January 2, 2025, the Company issued 250,000 RSAs to Mr. Ron Bentsur and 150,000 RSAs to each of Dr. Enrique Poradosu and Mr. Shay Shemesh. These RSAs vest over three years, withone-third vesting on each anniversary of the date of the grant, conditioned upon their continuing service.

On January 4, 2024, the Company issued 130,000 RSAs to each of Dr. Enrique Poradosu and Mr. Shay Shemesh (the “January 2024 Grants”). These RSAs vest over three years, withone-third vesting on each anniversary of the date of the grant, conditioned upon their continued service. On January 2, 2025, the vesting of the first one-third of the January 2024 Grants was extended to July 15, 2025. On July 12, 2025, the vesting of the first one-third of the January 2024 Grants was extended to January 3, 2026.

On January 12, 2023, the Company issued 210,000 RSAs to Mr. Ron Bentsur and 115,000 RSAsto each of Dr. Enrique Poradosu and Mr. Shay Shemesh (the “January 2023 Grants”). These RSAs vest over three years, withone-third vesting on each anniversary of the date of the grant, conditioned upon their continuing service. On January 2, 2025, the vesting requirement for the first two-thirds of the January 2023 Grants was extended to July 15, 2025, and the final third vests on January 12, 2026. On July 12, 2025, the vesting of the first two-thirds of the January 2023 Grants was extended to January 3, 2026.

On April 1, 2022, the Company issued 120,000 RSAs to Mr. Bentsur and 60,000 RSAsto each of Dr. Poradosu and Mr. Shemesh (the “April 2022 Grants”). These RSAs vest over three years, withone-third vesting on each anniversary of the date of the grant, conditioned upon their continuing service. On January 2, 2025, the full vesting of the April 2022 Grants was extended to July 15, 2025. On July 12, 2025, the vesting of the April 2022 Grants was extended to January 3, 2026.

On July 27, 2021, Mr. Bentsur, Dr. Poradosu, and Mr. Shemesh were granted 96,759 RSAs,48,399 RSAs, and 48,399 RSAs, respectively, which were not part of the Incentive Plan and excluded from the table above. On January 2, 2025, the vesting of the July 2021 grants to Mr. Bentsur, Dr. Poradosu, and Mr. Shemesh was extended to July 15, 2025. On July 12, 2025, the vesting of the grants was extended to January 3, 2026. In each case, such vesting requirements are contingent upon continued service.

Share Compensation Expense

For the three months ended September 30, 2025, the Company recognized expenses of $0.6 million as part of general and administrative expenses and $0.9 million as part of research and development expenses. For the three months ended September 30, 2024, the Company recognized expenses of $0.4 million as part of general and administrative expenses and $0.7 million as part of research and development expenses.

For the nine months ended September 30, 2025, the Company recognized expenses of $1.9 million as part of general and administrative expenses and $2.6 million as part of research and development expenses. For the nine months ended September 30, 2024, the Company recognized expenses of $1.4 million as part of general and administrative expenses and $2.3 million as part of research and development expenses.

NOTE 6 – NET LOSS PER SHARE:

Basic net loss per share is calculated by dividing the net loss attributable to the Company’s stockholders by the weighted average number of common shares outstanding.

Basic loss per share is calculated by dividing the result attributable to equity holders of the Company by the weighted average number of shares of common stock in issue during the period.

The following potentially dilutive securities were excluded from the calculation of diluted net loss per common share because their effect would have been anti-dilutive for the periods presented:

NOTE 7 – SEGMENT REPORTING:

Management does not segregate its business for internal reporting. The Company's Chief Operating Decision Maker (“CODM”), who is the CEO, evaluates the Company's performance based on its unified internal reporting, which is consistent with the presentation in the Company’s financial statements.

Net loss is used to monitor budget versus actual results.

The CODM uses many quantitative and qualitative factors, including net loss and quarterly cash burn, in benchmarking the Company to its competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment and in establishing management’s compensation.

Significant segment expenses are presented in the Company’s statements of operations. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s statements of operations, are presented below:

• • Other Segment Items included in net loss includes finance income.

NOTE 8– SUBSEQUENT EVENTS: